HC Wainwright reissued their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $20.00 target price on the stock. Separately, Wedbush restated an outperform rating and issued a $11.00 price target on shares of Aprea Therapeutics in a […]

View Entire Post